When Chapter 11 Pays in Warrants: Inotiv's June Filing and the New Currency of Reorganization

On June 3, 2026, Inotiv, Inc. (NASDAQ: NOTV) commenced voluntary Chapter 11 proceedings in the Southern District of Indiana. The filing carries the standard hallmarks of a distressed restructuring — existing equity classified as impaired, all current shares to be cancelled with no distribution, and an event of default that immediately accelerated obligations across multiple debt instruments. What is notable for warrant-focused readers is buried in the recovery waterfall: secured creditors and noteholders are receiving new equity and warrants as their recovery, while general unsecured claims are expected to be reinstated in full.

This is not an isolated structure. Over the last 24 months, we have catalogued a quiet but consistent shift in how Chapter 11 reorganizations distribute value: warrants are now the dominant second-instrument in the post-petition cap table, sitting alongside new common equity in the recovery package handed to noteholders. The result is that bankruptcy estates — including accelerator estates — are exporting large pools of warrants into private hands, where the rules of enforceability written in In re Astralabs / Newchip (W.D. Tex., 2024) now govern.

What the Inotiv plan does

Per the 8-K filed on June 3, 2026, Inotiv's restructuring support agreement contemplates three structural elements relevant to allocators tracking warrant issuance:

• Equity cancellation. All existing common shares are classified as impaired and slated for cancellation with no distribution. The plan filings explicitly warn current shareholders of a total loss.
• New-equity-plus-warrants recovery to secured and noteholder classes. The reorganized entity will issue new common equity and warrants to the senior debt classes, with the warrant tranche providing upside participation if post-emergence operations recover.
• Reinstatement of trade unsecureds. General unsecured creditors are expected to be made whole — an unusual posture that signals the estate is being preserved as an operating business rather than liquidated.

The structure mirrors what we have seen across half a dozen 2025-2026 filings (most prominently in life sciences and specialty pharma): warrants are the variable-payoff piece of the recovery, allowing senior creditors to take a haircut on principal in exchange for participation in a re-rated equity story.

Why warrants have become reorganization currency

Three structural drivers explain the trend, and all three are relevant to how the resulting instruments trade in the secondary market:

1. Tax efficiency for noteholders. Receiving warrants alongside new equity allows lenders to defer recognition on the upside portion of their recovery. The warrant is treated as an option for U.S. federal tax purposes — not as ordinary or capital income at issuance — which preserves optionality for the recipient and avoids forcing a recognition event the moment the plan is confirmed.

2. Dilution control for the reorganized issuer. Warrants delay the dilution to a strike-price-triggered moment. A reorganized issuer can emerge with a tighter post-emergence float and still offer noteholders meaningful upside, which makes the plan easier to confirm and easier to support with new-money financing.

3. Severability from the operating company. This is the doctrinal point that allocators most often miss. The In re Astralabs / Newchip rulings established that warrants issued by a debtor are severable from the debtor's underlying service obligations and freely transferable in bankruptcy — meaning the trustee, the noteholder, or any downstream purchaser can transact the instrument independent of whatever the issuer originally promised to provide. Judge Shad Robinson's framework, now four rulings deep and with two years of precedent, has effectively turned warrants into a clean asset class for Chapter 7 and Chapter 11 distributions alike.

The enforceability framework allocators should be reading

For LPs and operator-allocators evaluating warrants that originate in a reorganization — whether received directly as a noteholder or acquired in the secondary market — the practical due diligence questions track our standard warrant-enforcement checklist:

• Instrument clarity. Is the document a warrant, a contingent value right, a SAFE, or a synthetic? Each carries different transfer mechanics and different treatment under Section 1145 of the Bankruptcy Code (which exempts certain plan-issued securities from registration).
• Severability. Did the plan release the issuer's service or performance obligations? Newchip-style severability is now the default in most well-drafted plans, but older instruments and one-off restructurings can still leave performance hooks attached.
• Cap-table mechanics. What is the beneficial-ownership blocker (typically 4.99% or 9.99%)? How is the reorganized issuer's share count defined — pre-emergence shares, post-emergence shares, or shares outstanding immediately after any single exercise?
• Notice and exercise plumbing. Who is the transfer agent? What constitutes valid delivery of exercise notice? Bankruptcy-issued warrants frequently designate a special agent for a defined window; missing the window is a common failure mode.
• Reporting cadence. The third Newchip ruling held that issuer-side reporting requirements can extend a warrant's life if the obligee cannot demonstrate compliance. This is the single most overlooked clause in accelerator and reorganization paperwork.

Connecting Inotiv to the broader warrant landscape

Inotiv joins a 2026 cohort of Chapter 11 cases — alongside a meaningful number of micro-cap and specialty-pharma reorganizations — in which warrants are the dominant non-equity recovery instrument. The Newchip precedent is what makes those warrants tradable rather than stranded. Add to that the SEC's May 19, 2026 registered-offering reform proposal, which would preempt state blue-sky friction for many unlisted instruments and broaden Form S-3 access, and the operational picture for warrant-heavy portfolios looks materially cleaner than it did 18 months ago.

For the warrant research desk at AdValorem, the takeaway is that every Chapter 11 filing in 2026 should now be read as a potential warrant-issuance event. The economics of the recovery are reported in the plan; the enforceability is governed by the Newchip framework; and the secondary tradability is increasingly priced into the secondary market for distressed equity claims.

Educational takeaway

Warrants are no longer a sidecar instrument in bankruptcy plans — they are the structural medium through which reorganization upside is distributed to senior creditors. Reading a 2026 reorganization without parsing the warrant tranche means reading only half of the recovery. The AdValorem warrant research vertical — which publishes severability case notes, the Newchip doctrine summary, and ongoing enforcement framework updates — treats these instruments as a coherent asset class rather than a footnote. Inotiv's June 3 filing is a clean, current example of why the framework matters.